SEC-sourced researchBeta
ABBV
AbbVie Inc.
Company comparison ↗
Data passport
- CIK
- 0001551152
- Exchange
- NYSE
- Business activity
- — · SIC 2834
- Financial inputs
- 5/6
- Filing date
- Oct 5, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 54,318,000,000.0000 | Feb 20, 2026 |
| December 2024 | 56,334,000,000.0000 | Feb 20, 2026 |
| December 2025 | 61,160,000,000.0000 | Feb 20, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 61,160,000,000.0000 | 4,226,000,000.0000 | 19,030,000,000.0000 | 133,960,000,000.0000 | — | Feb 20, 2026 |
| December 2024 | 56,334,000,000.0000 | 4,278,000,000.0000 | 18,806,000,000.0000 | 135,161,000,000.0000 | — | Feb 20, 2026 |
| December 2023 | 54,318,000,000.0000 | 4,863,000,000.0000 | 22,839,000,000.0000 | — | — | Feb 20, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenues | $61.16B | December 2025 | Feb 20, 2026 | 10-K |
| Previous period revenueRevenues | $56.33B | December 2024 | Feb 20, 2026 | 10-K |
| Net incomeNetIncomeLoss | $4.23B | December 2025 | Feb 20, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $19.03B | December 2025 | Feb 20, 2026 | 10-K |
| Total assetsAssets | $133.96B | December 2025 | Feb 20, 2026 | 10-K |
| Total liabilities | — | — | — | — |